After Lariat LAA Ligater Disappoints in aMAZE, is a Path Ahead Still Possible?
Adjunctive left atrial appendage (LAA) ligation failed to increase the efficacy of catheter pulmonary vein isolation (PVI) in the aMAZE trial, though it appeared safe enough for further clinical investigation. In a population of people with nonparoxysmal atrial fibrillation (Afib), LAA ligation plus PVI was associated with no better primary effectiveness by 12 months — […]
Amulet vs Watchman Comparison Still Muddy Any Which Way LAA Leaks Are Defined
SAN FRANCISCO — Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the Amplatzer Amulet and the Watchman 2.5/FLX, the incidence of patent LAAs at 13 months reached 53.6% and 48.8%, respectively, on coronary CT angiography (risk ratio [RR] […]